Three to four mRNA COVID-19 vaccine in multiple sclerosis patients on immunosuppressive drugs: seroconversion and variants neutralization
Description
BACKGROUND: An enhanced SARS-CoV-2 vaccine regimen could improve humoral vaccine response in patients with multiple sclerosis (MS) treated by anti-CD20. We aimed to evaluate the serological response and the neutralizing activity after BNT162b2
